Loading stock data…
$41.19+0.94 (+2.34%)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Vericel Corporation in the Healthcare sector is trading at $41.19 with a market capitalization of $2.3B. Wall Street consensus targets $60.57 (7 analysts), implying a +47.1% move over the next 12 months. The stock is currently 16% below its 52-week high of $49.32, remaining 7.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $77.46M↑ | $68.42M↓ | $92.92M↑ | $67.50M↑ | $63.24M |
| Gross Profit | $56.40M↑ | $49.27M↓ | $73.13M↑ | $49.59M↑ | $46.61M |
| Operating Income | $434,000↑ | -$8.06M↓ | $22.41M↑ | $3.45M↑ | -$2.03M |
| Net Income | $2.21M↑ | -$6.30M↓ | $23.24M↑ | $5.07M↑ | -$553,000 |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North Ame...